NCT05858983View on ClinicalTrials.gov

Gene Therapy in Subjects With Biallelic RPE65 Mutation-associated Retinal Dystrophy

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 30, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2029

Conditions
Biallelic RPE65 Mutation-associated Retinal Dystrophy
Interventions
GENETIC

FT-001 Low Dose

Comparison of different dosages of FT-001

GENETIC

FT-001 Mid Dose

Comparison of different dosages of FT-001

GENETIC

FT-001 High Dose

Comparison of different dosages of FT-001

Trial Locations (1)

100142

RECRUITING

Peking Union Medical College Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Frontera Therapeutics

INDUSTRY

NCT05858983 - Gene Therapy in Subjects With Biallelic RPE65 Mutation-associated Retinal Dystrophy | Biotech Hunter | Biotech Hunter